Efficacy of serum apelin and galectin‐3 as potential predictors of mortality in severe COVID‐19 patients

Apelin is a cardioprotective biomarker while galectin‐3 is a pro‐inflammatory and profibrotic biomarker. Endothelial dysfunction, hyperinflammation, and pulmonary fibrosis are key mechanisms that contribute to the development of adverse outcomes in Coronavirus disease 2019 (COVID‐19) infection. This...

Full description

Saved in:
Bibliographic Details
Published in:Journal of medical virology 2023-02, Vol.95 (2), p.e28494-n/a
Main Authors: Berber, Nurcan Kırıcı, Geçkil, Ayşegül Altıntop, Altan, Nazife Özge, Kıran, Tuğba Raika, Otlu, Önder, Erdem, Mehmet, İn, Erdal
Format: Article
Language:English
Subjects:
Albumins
Apelin
biomarker
Biomarkers
Confidence intervals
Coronaviruses
COVID-19
Ferritin
Fibrosis
Galectin 3
Humans
Inflammation
Lung diseases
Mortality
Patients
Prognosis
Regression analysis
Statistical analysis
Survival
Viral diseases
Virology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Apelin is a cardioprotective biomarker while galectin‐3 is a pro‐inflammatory and profibrotic biomarker. Endothelial dysfunction, hyperinflammation, and pulmonary fibrosis are key mechanisms that contribute to the development of adverse outcomes in Coronavirus disease 2019 (COVID‐19) infection. This study aims to analyze the prognostic value of serum apelin and galectin‐3 levels to early predict patients at high risk of mortality in patients hospitalized for severe COVID‐19 pneumonia. The study included 78 severe COVID‐19 patients and 40 healthy controls. The COVID‐19 patients were divided into two groups, survivors and nonsurvivors, according to their in‐hospital mortality status. Basic demographic and clinical data of all patients were collected, and blood samples were taken before treatment. In our study, serum apelin levels were determined to be significantly lower in both nonsurvivor and survivor COVID‐19 patients compared to the control subjects (for both groups, p  0.05). Serum galectin‐3 levels were determined to be higher in a statistically significant way in nonsurvivors compared to survivors and controls (for both groups; p 
ISSN:0146-6615
1096-9071
DOI:10.1002/jmv.28494